Healthcare Industry News: Transdermal
News Release - September 20, 2006
ProEthic Pharmaceuticals Promotes Roger Graben to Vice President, Business DevelopmentMONTGOMERY, Ala.--(HSMN NewsFeed)--Sept. 20, 2006--ProEthic Pharmaceuticals, Inc., a privately funded specialty pharmaceutical company that acquires, develops and markets niche prescription products, announced today that it has promoted Roger Graben, Ph.D., R.Ph. to Vice President, Business Development. Dr. Graben will oversee all aspects of ProEthic's licensing and business development activities to increase the Company's product development pipeline and product portfolio. This will include exploring both in-licensing and out-licensing opportunities.
Prior to this promotion, Dr. Graben served as ProEthic's Director of Manufacturing, where he oversaw all aspects of the Company's in-house formulation development and manufacturing.
"We are excited to have Dr. Graben fulfill this role, as we look to expand our product opportunities," stated Carl Whatley, chairman and chief executive officer, ProEthic Pharmaceuticals.
Prior to his work at ProEthic, Dr. Graben joined Solvay Pharmaceuticals in 1987 as a Research Scientist in Pharmaceutical Research and Development. Formulation projects included solid dose, Transdermal, liquid, and semi-solid dosage forms, as well as a patentable coating based drug delivery system. In 1992, Dr. Graben joined Chelsea Labs (a Rugby Generics/Marion Merrill-Dow Company) as Manager of Pharmaceutical Technology and later as Director of QA/QC. Responsibilities included technology transfer, scale-up/validation, production trouble shooting, and all GMP manufacturing site QA, QC, and Compliance activities.
From 1996-2003, Dr. Graben owned an independent drug store, worked as an industry consultant, and founded a small pharmaceutical company. He served as a Research Associate at the Auburn University Harrison School of Pharmacy from 2004 to 2006 where he sought industry funding for and performed formulation development projects while also working with industry and economic development groups to promote the growth of the pharmaceutical and biotechnology industry in Alabama.
About ProEthic Pharmaceuticals, Inc.
ProEthic is a privately funded specialty pharmaceutical company that acquires, develops and markets niche prescription products. ProEthic markets branded prescription allergy, respiratory, pain and men's prostate vitamin products to general and family practitioners and selected specialty physicians in rural and suburban markets in 31 states. The company develops and commercializes proprietary formulations of previously approved compounds and selectively seeks regulatory approval to market well-characterized compounds for new therapeutic indications. ProEthic has built its product portfolio and development pipeline through a combination of internal development and acquisition of late-stage drug candidates. It also markets niche generic prescription pharmaceutical products through Midlothian Laboratories LLC, a wholly owned subsidiary.
Source: ProEthic Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.